表面活性剂替代疗法作为COVID-19的有希望的治疗方法:更新的叙事审查
Khaled Khudadah1, Alaa Ramadan2, Ahmed Othman1
1Kuwait Oil Company Ahmadi Hospital, Al Ahmadi, Kuwait.
Bioscience reports
|July 27, 2023
概括
外源表面活性剂治疗对COVID-19呼吸困难有希望,改善肺功能但不提高死亡率. 需要进行进一步的试验,以优化表面活性剂的使用,并探索其药物递送潜力.
科学领域:
- 肺部医学 肺部医学
- 病毒学 病毒学
- 关键的护理关键的护理
背景情况:
- COVID-19的症状与新生儿呼吸困扰综合征相同.
- SARS-CoV-2 准2型膜细胞,损害表面活性剂的产生,并导致急性呼吸困扰.
- 组织病理学证实了COVID-19患者的脱皮膜细胞.
研究的目的:
- 审查有关外源表面活性剂治疗COVID-19的当前文献.
- 评估表面活性剂在改善呼吸系统参数和死亡率方面的有效性.
- 探索表面活性剂作为药物输送载体的潜力.
主要方法:
- 对COVID-19中表面活性剂治疗现有文献和临床试验的审查.
- 对接受治疗的患者呼吸系统参数和死亡率数据的分析.
- 讨论表面活性剂在药物输送系统中的作用.
主要成果:
- 表面活性剂治疗导致COVID-19患者呼吸系统参数显著改善.
- 没有观察到对死亡率的重大影响,需要进一步调查.
- 突出了表面活性剂作为脂质体药物载体的潜力.
结论:
- 外源表面活性剂疗法是COVID-19相关的呼吸困扰的有希望的治疗方法.
- 进一步的临床试验至关重要,以确定最佳的表面活性剂配方和施用方法,以减少死亡率.
- 表面活性剂具有针对药物输送的潜力,需要先进的研究努力.
相关概念视频
Breathing
59.7K
The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
59.7K
Acute Respiratory Failure-V
165
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
165
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
265
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
265
Acute Respiratory Failure-II
277
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
277
Acute Respiratory Failure-I
250
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
250
COPD: Management Using Bronchodilators and Corticosteroids
244
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
244


